Antigens, Neoplasm/metabolism; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Biomarkers, Tumor/metabolism; Breast Neoplasms/drug therapy; Breast Neoplasms/metabolism; Carcinoma, Ductal, Breast/drug therapy; Carcinoma, Ductal, Breast/metabolism; Carcinoma, Lobular/drug therapy; Carcinoma, Lobular/metabolism; DNA Topoisomerases, Type II/metabolism; DNA-Binding Proteins/metabolism; Adult; Antigens, Neoplasm/genetics; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Biomarkers, Tumor/genetics; Breast Neoplasms/genetics; Breast Neoplasms/surgery; Capecitabine; Carcinoma, Ductal, Breast/genetics; Carcinoma, Ductal, Breast/surgery; Carcinoma, Lobular/genetics; Carcinoma, Lobular/surgery; Chemotherapy, Adjuvant; DNA Topoisomerases, Type II/genetics; DNA-Binding Proteins/genetics; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Disease-Free Survival; Docetaxel; Epirubicin/administration & dosage; Female; Fluorouracil/administration & dosage; Fluorouracil/analogs & derivatives; Gene Expression; Genes, erbB-2/genetics; Humans; Immunochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen/metabolism; Middle Aged; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptors, Estrogen/metabolism; Receptors, Progesterone/metabolism; Retrospective Studies; Survival Analysis; Taxoids/administration & dosage; Treatment Outcome